Opinion on Immunology and Inflammation

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Schering-Plough/Centocor: wider Remicade indication

Published By Datamonitor
06 Feb 2001
CommentWire
CommentWire

Merck/Pfizer/Pharmacia: study favors Celebrex

Published By Datamonitor
21 Mar 2001
ResearchWire
ResearchWire

Arthritis: sales will hit $24 billion in 2007

Published By Datamonitor
23 Apr 2001
CommentWire
CommentWire

DePuy/BTG: orthopedic powerhouse to drive hyaluronic acid

Published By Datamonitor
08 Aug 2001
Expert View
Expert View

Proteins in peril

Published By Datamonitor
10 Aug 2001
CommentWire
CommentWire

Pfizer/Pharmacia: study erodes Celebrex's advantages

Published By Datamonitor
22 Aug 2001
Expert View
Expert View

Arthritis: saturation strategies

Published By Datamonitor
31 Aug 2001
Expert View
Expert View

UK Arthritis Sufferers Receiving Second Best in Pain Medication

Many rheumatoid and osteoarthritis sufferers in the UK may have to settle for second best in pain medication and are being put at risk of developing serious gastrointestinal side effects (GI) according to market analysts, Datamonitor.

Published By Datamonitor
20 Feb 2002
CommentWire
CommentWire

Amgen: Kineret combination approved across EU

The approval for a Kineret/methotrexate combination for rheumatoid arthritis (RA) patients is a major advance for Amgen, since national formularies across Europe will now list the combination therapy as a valid second-line treatment. The ruling should open up Amgen's market, allowing it to grab market share from other drugs currently used in second-line therapy.

Published By Datamonitor
15 Mar 2002
Expert View
Expert View

Merck: the victim of definitions

Merck has been forced to concede ground to its rival Pharmacia over the development of COX-II inhibitors, predominantly used for the relief of signs and symptoms of arthritis. The big pharma has withdrawn its application for Arcoxia's FDA approval - but how severe will the cost of the drug's false start prove?

Published By Datamonitor
05 Apr 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.